Novavax, Inc.

Novavax, Inc., along with its wholly owned subsidiaries, focuses on addressing global health challenges using its scientific expertise in vaccines and its technology platform, which includes its Matrix-M™ adjuvant and protein-based nanoparticles. The company's growth strategy involves maximizing the impact of its technology by forming partnerships for its Matrix-M™ adjuvant and research and development (R&D) assets, while maintaining a focused operating model. The proprietary Matrix-M™ adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. This technology platform is used in the company's authorized COVID-19 Vaccine (Nuvaxovid) and the R21/Matrix-M™ adjuvant malaria vaccine. Novavax is also advancing its pipeline programs, focusing on high-value assets in areas with unmet medical needs. The company provides its Matrix-M™ adjuvant for use in collaborations, such as with the R21/Matrix-M™ adjuvant malaria vaccine, developed by the Jenner Institute, University of Oxford, and manufactured by Serum Institute of India Pvt. Ltd. The R21/Matrix-M™ adjuvant malaria vaccine is authorized in several countries. Additionally, Novavax provides Matrix-M™ adjuvant for various preclinical and clinical stage programs, and preclinical investigations, including material transfer agreements with global pharmaceutical companies for exploring its use in their pipelines, such as a preclinical collaboration in oncology. Novavax was incorporated in 1987 under the laws of the State of Delaware.